ViaCyte said today that it will begin clinical trials of its novel islet cell replacement therapy in development as a potential cure for Type I diabetes, after landing regulatory wins from the FDA and Health Canada.
The company’s PEC-Direct candidate delivers stem cell-derived pancreatic progenitor cells in a device that is designed to enable direct vascularization of the cells. Following implantation, ViaCyte said the cells can proliferate and mature into human islet tissue that can produce insulin. The therapy is being developed for Type I diabetes patients who are at high risk for acute, life-threatening complications.
Get the full story at our sister site, Drug Delivery Business News.